Kurs
0,00%
Likviditet
0,76 MSEK
Kalender
| Tid* | ||
| 2025-05-06 | N/A | Årsstämma |
| 2025-02-12 | 12:00 | Bokslutskommuniké 2024 |
| 2024-11-07 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-29 | - | Kvartalsrapport 2024-Q2 |
| 2024-07-30 | - | Split QLIFE 2000:1 |
| 2024-05-28 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-08 | - | X-dag ordinarie utdelning QLIFE 0.00 SEK |
| 2024-05-07 | - | Årsstämma |
| 2024-02-08 | - | Bokslutskommuniké 2023 |
| 2024-01-16 | - | Extra Bolagsstämma 2023 |
| 2023-11-13 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-17 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-26 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-05 | - | X-dag ordinarie utdelning QLIFE 0.00 SEK |
| 2023-05-04 | - | Årsstämma |
| 2023-03-24 | - | Extra Bolagsstämma 2022 |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-11-25 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-29 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-06 | - | X-dag ordinarie utdelning QLIFE 0.00 SEK |
| 2022-05-05 | - | Årsstämma |
| 2022-05-05 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-11-08 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-16 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-06 | - | X-dag ordinarie utdelning QLIFE 0.00 SEK |
| 2021-05-05 | - | Årsstämma |
| 2021-05-05 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-11-19 | - | Extra Bolagsstämma 2020 |
| 2020-11-18 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-18 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-22 | - | X-dag ordinarie utdelning QLIFE 0.00 SEK |
| 2020-05-20 | - | Årsstämma |
| 2020-05-20 | - | Kvartalsrapport 2020-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Qlife Holding AB ("Qlife" or the "Company") and Atlas Special Opportunities, LLC ("Atlas"), have entered into a non-binding term sheet on 13 May 2024. According to the term sheet, Atlas will fund the Company with up to SEK 30.00 million in ten (10) tranches of different sizes. Further, the called loan amounts can be converted into new shares. Qlife will communicate the outcome of the ongoing negotiations to the market as soon as concrete information becomes available.
This disclosure contains information that Qlife Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 2024-06-10 15:08 CET
Thomas Warthoe
Chief Executive Officer (CEO)
Phone: +45 21 63 35 34
E-mail: tw@egoo.health